Actavis and Warner Chilcott say they are in early discussions about a possible combination

NEW YORK, N.Y. – The drugmakers Actavis Inc. and Warner Chilcott PLC say they are holding early discussions about a possible combination of the two companies.

The companies say there is no guarantee that Actavis will make an offer for Warner Chilcott.

Actavis expects to generate more than $8.1 billion in revenue this year while Warner Chilcott expects raise about $2.3 billion to $2.4 billion.

Actavis was formed in October through a $5.6 billion combination of Watson Pharmaceuticals of New Jersey and Actavis of Switzerland. It is one of the world’s biggest generic drug companies.

Warner Chilcott is based in Ireland and sells the ulcerative colitis drugs Asacol and Delzicol, osteoporosis drug Actonel, and several oral contraceptives.

Warner Chilcott shares rose 22 per cent in afternoon trading after the disclosure of the talks. Actavis is up more than 11 per cent.

News from © The Associated Press, . All rights reserved.
This material may not be published, broadcast, rewritten or redistributed.

The Associated Press

The Associated Press is an independent global news organization dedicated to factual reporting. Founded in 1846, AP today remains the most trusted source of fast, accurate, unbiased news in all formats and the essential provider of the technology and services vital to the news business. More than half the world’s population sees AP journalism every day.